92 related articles for article (PubMed ID: 9245488)
21. In vitro effect of recombinant human tumor necrosis factor-alpha on canine neutrophil apoptosis.
Oguma K; Sano J; Kano R; Watari T; Hasegawa A
Res Vet Sci; 2006 Apr; 80(2):162-6. PubMed ID: 16040067
[TBL] [Abstract][Full Text] [Related]
22. The antitumor effect of intraperitoneal treatment with rhTNF-alpha muteins on Ehrlich ascites tumor growth.
Terlikowski S; Nowak HF
Cancer Biother Radiopharm; 2000 Feb; 15(1):39-46. PubMed ID: 10740651
[TBL] [Abstract][Full Text] [Related]
23. Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor alpha in mouse models.
Gasparri A; Moro M; Curnis F; Sacchi A; Pagano S; Veglia F; Casorati G; Siccardi AG; Dellabona P; Corti A
Cancer Res; 1999 Jun; 59(12):2917-23. PubMed ID: 10383155
[TBL] [Abstract][Full Text] [Related]
24. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
[TBL] [Abstract][Full Text] [Related]
25. Antitumor activity of tumor necrosis factor-alpha conjugated with polyvinylpyrrolidone on solid tumors in mice.
Kamada H; Tsutsumi Y; Yamamoto Y; Kihira T; Kaneda Y; Mu Y; Kodaira H; Tsunoda SI; Nakagawa S; Mayumi T
Cancer Res; 2000 Nov; 60(22):6416-20. PubMed ID: 11103807
[TBL] [Abstract][Full Text] [Related]
26. Combination of tumor necrosis factor-alpha with sulindac augments its apoptotic potential and suppresses tumor growth of human carcinoma cells in nude mice.
Yasui H; Adachi M; Imai K
Cancer; 2003 Mar; 97(6):1412-20. PubMed ID: 12627504
[TBL] [Abstract][Full Text] [Related]
27. PEGylated recombinant human tumor necrosis factor alpha: preparation and anti-tumor potency.
Li YP; Pei YY; Ding J; Shen ZM; Zhang XY; Gu ZH; Zhou JJ
Acta Pharmacol Sin; 2001 Jun; 22(6):549-55. PubMed ID: 11747763
[TBL] [Abstract][Full Text] [Related]
28. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM
Br J Cancer; 1999 May; 80(5-6):716-23. PubMed ID: 10360649
[TBL] [Abstract][Full Text] [Related]
29. Safety and antitumor activity of recombinant soluble Apo2 ligand.
Ashkenazi A; Pai RC; Fong S; Leung S; Lawrence DA; Marsters SA; Blackie C; Chang L; McMurtrey AE; Hebert A; DeForge L; Koumenis IL; Lewis D; Harris L; Bussiere J; Koeppen H; Shahrokh Z; Schwall RH
J Clin Invest; 1999 Jul; 104(2):155-62. PubMed ID: 10411544
[TBL] [Abstract][Full Text] [Related]
30. Clioquinol promotes cancer cell toxicity through tumor necrosis factor alpha release from macrophages.
Du T; Filiz G; Caragounis A; Crouch PJ; White AR
J Pharmacol Exp Ther; 2008 Jan; 324(1):360-7. PubMed ID: 17940196
[TBL] [Abstract][Full Text] [Related]
31. Novel muteins of human tumor necrosis factor with potent antitumor activity and less lethal toxicity in mice.
Kuroda K; Miyata K; Shikama H; Kawagoe T; Nishimura K; Takeda K; Sakae N; Kato M
Int J Cancer; 1995 Sep; 63(1):152-7. PubMed ID: 7558445
[TBL] [Abstract][Full Text] [Related]
32. Tissue distribution of recombinant human tumor necrosis factor alpha derivative in mice.
Chai BX; Tang ZM; Liu XW; Tu M
Zhongguo Yao Li Xue Bao; 1999 Apr; 20(4):371-4. PubMed ID: 10452128
[TBL] [Abstract][Full Text] [Related]
33. Preventive effects of a biscoclaurine alkaloid, cepharanthine, on endotoxin or tumor necrosis factor-alpha-induced septic shock symptoms: involvement of from cell death in L929 cells and nitric oxide production in raw 264.7 cells.
Sakaguchi S; Furusawa S; Wu J; Nagata K
Int Immunopharmacol; 2007 Feb; 7(2):191-7. PubMed ID: 17178386
[TBL] [Abstract][Full Text] [Related]
34. Antitumor activity of tumor necrosis factor alpha conjugated with divinyl ether and maleic anhydride copolymer on solid tumors in mice.
Kaneda Y; Yamamoto Y; Kamada H; Tsunoda S; Tsutsumi Y; Hirano T; Mayumi T
Cancer Res; 1998 Jan; 58(2):290-5. PubMed ID: 9443407
[TBL] [Abstract][Full Text] [Related]
35. Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency.
Yoshioka Y; Tsutsumi Y; Ikemizu S; Yamamoto Y; Shibata H; Nishibata T; Mukai Y; Okamoto T; Taniai M; Kawamura M; Abe Y; Nakagawa S; Nagata S; Yamagata Y; Mayumi T
Biochem Biophys Res Commun; 2004 Mar; 315(4):808-14. PubMed ID: 14985084
[TBL] [Abstract][Full Text] [Related]
36. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice.
Hao C; Song JH; Hsi B; Lewis J; Song DK; Petruk KC; Tyrrell DL; Kneteman NM
Cancer Res; 2004 Dec; 64(23):8502-6. PubMed ID: 15574753
[TBL] [Abstract][Full Text] [Related]
37. Adverse effects of tumour necrosis factor in cyclophosphamide-treated mice subjected to gut-derived Pseudomonas aeruginosa sepsis.
Matsumoto T; Tateda K; Miyazaki S; Furuya N; Ohno A; Ishii Y; Hirakata Y; Yamaguchi K
Cytokine; 1997 Oct; 9(10):763-9. PubMed ID: 9344509
[TBL] [Abstract][Full Text] [Related]
38. Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid.
Browne WL; Wilson WR; Baguley BC; Ching LM
Anticancer Res; 1998; 18(6A):4409-13. PubMed ID: 9891501
[TBL] [Abstract][Full Text] [Related]
39. Recombinant human tumour necrosis factor-alpha (rhTNF-alpha) and rhTNF-alpha analogue enhance amyloid deposition in the Syrian hamster.
Niewold TA; Gruys E; Arakawa T; Shirahama T; Kisilevsky R
Scand J Immunol; 1993 Jan; 37(1):29-32. PubMed ID: 8418469
[TBL] [Abstract][Full Text] [Related]
40. Tumor necrosis factor alpha (rhTNF) fails to stimulate angiogenesis in the rabbit cornea.
Phillips GD; Stone AM; Schultz JC; Jones BD; Lisowski MJ; Goodkin ML; Knighton DR
Anat Rec; 1996 May; 245(1):53-6. PubMed ID: 8731040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
